Case Study: Genmab accelerates non-clinical drug development with Certara SEND Explorer

Transforming Non-clinical Drug Development with SEND Explorer

Genmab, a biopharmaceutical company focused on developing cancer treatments, faced significant challenges in analyzing complex non-clinical toxicology data from their outsourced studies. Their scientists had limited access to interim data, struggled to visualize specialized immunology information, and found cross-study comparisons to be a manual and time-consuming process. To address this, they turned to vendor Certara and its SEND Explorer software.

Certara implemented its SEND Explorer solution, which provided an intuitive interface for rapid data visualization and cross-study meta-analysis. This allowed Genmab to perform interim analyses on ongoing studies and drastically reduced the time required to create visualizations from hours to minutes. The implementation saved substantial time, improved efficiency, and streamlined Genmab's communications with regulatory agencies, ultimately accelerating their non-clinical safety timelines.

Genmab